Your browser doesn't support javascript.
loading
Recurrent Liver Allograft Injury in Patients With Donor-Derived Malignancy Treated With Immunosuppression Cessation and Retransplantation.
Lee, Brian T; Ganjoo, Naveen; Fiel, M Isabel; Hechtman, Jackie F; Sarkar, Suparna A; Kim-Schluger, Leona; Florman, Sander S; Schiano, Thomas D.
Affiliation
  • Lee BT; Division of Gastroenterology and Transplantation Institute, Loma Linda University Health, Loma Linda, CA, USA.
  • Ganjoo N; Recanati/Miller Transplantation Institute, Division of Liver Diseases, Department of Medicine, New York, NY, USA.
  • Fiel MI; Recanati/Miller Transplantation Institute, Division of Liver Diseases, Department of Medicine, New York, NY, USA.
  • Hechtman JF; Department of Pathology, Molecular and Cell-Based Medicine, New York, NY, USA.
  • Sarkar SA; NeoGenomics Laboratories, Fort Meyers, FL, USA.
  • Kim-Schluger L; Department of Pathology, New York University School of Medicine, New York, NY, USA.
  • Florman SS; Recanati/Miller Transplantation Institute, Division of Liver Diseases, Department of Medicine, New York, NY, USA.
  • Schiano TD; Recanati/Miller Transplantation Institute, Division of Abdominal Transplantation, Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Am J Clin Pathol ; 158(2): 199-205, 2022 08 04.
Article in En | MEDLINE | ID: mdl-35285881
ABSTRACT

OBJECTIVES:

Donor-derived malignancy of the liver allograft is a rare but serious condition in the setting of necessary immunosuppression. Retransplantation after abrupt immunosuppression cessation has been performed with durable cancer-free survival.

METHODS:

We present 2 cases of patients with donor-derived malignancy who were treated with complete immunosuppression cessation, which induced rapidly progressive liver allograft rejection and failure, with a need for subsequent retransplantation. We reviewed all serial liver biopsies and explants from both patients and performed C4d immunostaining.

RESULTS:

Initial explants of both patients showed severe allograft rejection, with unusual features of sinusoidal obstruction syndrome and C4d positivity. Malignant tumors in the explants were necrotic, related to rejection of donor-derived cancer cells and tissue. Follow-up of both patients has shown long-term cancer-free survival but issues with recurrent allograft failure requiring a third transplant. The reasons for retransplantation in both cases were related to allograft failure from antibody-mediated rejection.

CONCLUSIONS:

Clinicians should be aware of a potentially increased risk of rejection and recurrent allograft failure when strategizing treatment of donor-derived malignancy with immunosuppression cessation and retransplantation.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Liver Transplantation / Neoplasms Limits: Humans Language: En Journal: Am J Clin Pathol Year: 2022 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Liver Transplantation / Neoplasms Limits: Humans Language: En Journal: Am J Clin Pathol Year: 2022 Document type: Article Affiliation country: United States